First Author: S.Masnec Olujić CROATIA
Co Author(s): M. Kalauz J. Škunca Herman I. Petric Vicković
Purpose:
Aim: To report the long-term results of 72 keratoconic eyes treated by riboflavin ultraviolet A collagen cross-linking
Setting:
: 1.Ghetaldus Ophthalmology Policlinics, Zagreb, Croatia
2.University Hospital Center Zagreb, Department of
Ophthalmology, Zagreb, Croatia
3.University Department of Ophthalmology,
University Hospital Center „Sestre milosrdnice“,
Zagreb, Croatia
Methods:
Patients and methods: Prospective study included 40 patients with progressive keratoconus (18 male, 22 female), 72 eyes were treated, from May 2007 through May 2011. Mean patient age was 28.3 ± 6.0, ranging 17- 35 years.
Examinations included uncorrected visual acuity, best spectacle-corrected and spherical spectacle-corrected visual acuity, slit-lamp examination, IOP measurement, endothelial cells count, corneal topography and surface aberrometry, tomography and optical pachymetry.
Minimal thickness of cornea in treated patients was 350 µm. Patients were treated with riboflavin and UVA light according to Theo Seiler et al. method.
Examination and follow ups were done preoperatively, 1.day, 7days, 1 month, 3 months, 6 months, and every year after the treatment, with the maximum follow-up of 4 years.
Results:
Results: 24 eyes showed regression of keratometric values, progression of keratoconus was stopped in 47 eyes. Progression was noticed in 1 patient in both eyes and delayed reepitelization was present in 8 eyes. One month after cross-linking, corneal haze was determined on slit lamp examination in 2% of eyes. Sterile infiltrates were seen in 5.2% of eyes. After six months all included keratoconic patiens that underwent treatment with cross-linking method, had completely translucent cornea.
Conclusions:
Conclusion: Riboflavin ultraviolet A corneal collagen cross-linking is a promising method that showed stabilisation in 97,22 % of our patients with keratoconus, and showed regression in 33.33% cases. The results of our study showed a long-term stability of keratoconus after cross-linking without relevant side effects.
Financial Disclosure:
No
